Organon & Co. (NYSE:OGN – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.
Institutional & Insider Ownership
77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 1.4% of Organon & Co. shares are held by company insiders. Comparatively, 0.8% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Organon & Co. and Aclarion, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Organon & Co. | 3 | 2 | 1 | 1 | 2.00 |
| Aclarion | 1 | 1 | 0 | 0 | 1.50 |
Earnings & Valuation
This table compares Organon & Co. and Aclarion”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Organon & Co. | $6.40 billion | 0.31 | $864.00 million | $1.92 | 4.02 |
| Aclarion | $50,000.00 | 83.75 | -$6.99 million | ($15.00) | -0.42 |
Organon & Co. has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Organon & Co. and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Organon & Co. | 7.95% | 143.47% | 7.14% |
| Aclarion | -10,908.50% | -67.53% | -63.01% |
Risk & Volatility
Organon & Co. has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.
Summary
Organon & Co. beats Aclarion on 13 of the 15 factors compared between the two stocks.
About Organon & Co.
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
